THE Pharmaceutical Benefits
Advisory Committee has
commissioned a post market
review of all anti-dementia drugs
listed on the PBS for the treatment
of Alzheimers disease: donepezil;
rivastigmine; galantamine; and
memantine.
As such the PBAC is now inviting
submissions to the Review - see
www.pbs.gov.au/info/reviews/antidementia-
drugs.
The above snippet is the first part of an article sent to subscribers in Pharmacy Daily's issue from 29 May 12
Established in 2007, Pharmacy Daily is Australia's leading pharmacy industry publication, and is sent as a free subscription to people across the industry as a PDF newsletter every weekday.
To sign up for a free subscription, click on the button at right.
